Kenmochi Toya Real Solo Live "KOKU FES." Live Viewing Confirmed!
TOKYO, Sept. 28, 2026 /PRNewswire/ -- Kenmochi Toya, one of the longstanding VTubers of NIJISANJI, is here to captivate audiences with his solo live concert, "Kenmochi Toya Real Solo Live【KOKU FES.】"taking place on Sunday, October 11, 2026, at...
Xsight Group Featured in Harvard Business Review on AI Agent Orchestration Across Silos
HONG KONG, Sept. 28, 2026 /PRNewswire/ -- Xsight Group (known as Xsight), a Hong Kong–headquartered cross-border technology group founded in 2004, has been featured as a research case in "How AI Agents Orchestrate Work Across Silos," a special...
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major...
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
New digital ecosystem delivers greater customer choice, deeper engagement and a more sustainable travel insurance model Allianz Partners launches the Metaportal to support changing rewards and loyalty programs. Greater customer choice through...
AI Memory & Storage: The 5th GMIF2026 Innovation Summit Successfully Concludes in Shenzhen
SHENZHEN, China, Sept. 26, 2026 /PRNewswire/ -- On September 23, the 5th GMIF2026 Innovation Summit successfully concluded at the Renaissance Shenzhen Bay Hotel. Co-hosted by the Shenzhen Memory Industry Association (SMIA) and School of Integrated...
2026 Beijing International Week for Science Literacy Launched in Beijing
BEIJING, Sept. 27, 2026 /PRNewswire/ -- The 2026 Beijing International Week for Science Literacy opened at the Beijing Science Center, running from September 22 to 26. Representatives of international organizations, universities, science museums and...
2026 IMS | IASO Bio Presented FUCASO China Real-World Data
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate...
2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective...